Pfizer vancomycin supplier Zhejiang Medicine warned by US FDA

By Gareth Macdonald

- Last updated on GMT

iStock/sigurcamp
iStock/sigurcamp
Pfizer supplier Zhejiang Medicine Co. should quiz staff to determine the extent of data integrity deficiencies at its API plant in Xinchang, China according to the US FDA.

The US Food and Drug Administration (FDA) made the suggestion in a warning letter​ published this week. The document also details problems observed at Zhejiang’s active pharmaceutical ingredient (API) manufacturing facility in June last year.

During the visit to the site - which is operated by Zhejiang 's Xinchang Pharmaceutical division - agency inspectors saw staff backdating API quality test results and conducting unofficial tests for residual solvents that were separate to official recorded analyses.

The FDA said a full investigation of the site’s quality system is required to determine the extent of inaccuracies in data records.

It also suggested Zhejiang interviews “current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.​”

In addition to the review, the FDA also wants Zhejiang to determine what impact the data failings have had on the quality of APIs made at the facility.

Response

Zhejiang – which is listed on the Shanghai Stock Exchange - makes ingredients for antibiotics, antidiabetic medicines and immunosuppressant drugs.

In a statement (here in Mandarin​) the firm said it “will take this opportunity to pay close attention to quality management, and effectively improve the level of compliance.”

According to its 2015 annual report, Zhejiang makes vancomycin for Pfizer’s Hospira​ division.

A World Health Organization report​ from 2012 states that Zhejiang's vancomycin activities are based at the Xinchang facility

Pfizer told us: "Zhejiang, Medicine Co Ltd, China currently supplies Vancomycin API to Hospira, Inc., a Pfizer company. 

"We have not seen any indication of any issues with the product.  Pfizer’s Quality Management Program includes measures to ensure that all products meet Pfizer’s quality standards before they are released into the market."

Zhejiang did not respond to a request for comment.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars